Annual SGA
$10.69 M
-$173.00 K-1.59%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual SGA is $10.69 million, with the most recent change of -$173.00 thousand (-1.59%) on December 31, 2023.
- During the last 3 years, BCLI annual SGA has risen by +$1.34 million (+14.30%).
- BCLI annual SGA is now -1.59% below its all-time high of $10.87 million, reached on December 31, 2022.
Performance
BCLI SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$2.00 M
-$57.00 K-2.77%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly SGA is $2.00 million, with the most recent change of -$57.00 thousand (-2.77%) on September 30, 2024.
- Over the past year, BCLI quarterly SGA has dropped by -$57.00 thousand (-2.77%).
- BCLI quarterly SGA is now -35.51% below its all-time high of $3.11 million, reached on December 31, 2023.
Performance
BCLI Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$878.04 M
-$14.23 M-1.65%
September 30, 2024
Summary
- As of February 8, 2025, BCLI TTM SGA is -$878.04 million, with the most recent change of -$14.23 million (-1.65%) on September 30, 2024.
- Over the past year, BCLI TTM SGA has dropped by -$887.43 million (-9456.83%).
- BCLI TTM SGA is now -1714831.64% below its all-time high of -$51.20 thousand.
Performance
BCLI TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
BCLI Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.6% | -2.8% | -9456.8% |
| 3 y3 years | +14.3% | -2.8% | -9456.8% |
| 5 y5 years | +85.3% | -2.8% | -9456.8% |
BCLI Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1.6% | +14.9% | -35.5% | +32.4% | -33.3% | at low |
| 5 y | 5-year | -1.6% | +84.5% | -35.5% | +35.4% | -104.3% | at low |
| alltime | all time | -1.6% | >+9999.0% | -35.5% | >+9999.0% | <-9999.0% | at low |
Brainstorm Cell Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.00 M(-2.8%) | $8.68 M(-7.5%) |
| Jun 2024 | - | $2.06 M(+36.2%) | $9.38 M(-6.0%) |
| Mar 2024 | - | $1.51 M(-51.3%) | $9.98 M(-6.7%) |
| Dec 2023 | $10.69 M(-1.6%) | $3.11 M(+14.8%) | $10.69 M(+6.4%) |
| Sep 2023 | - | $2.71 M(+1.9%) | $10.05 M(-3.5%) |
| Jun 2023 | - | $2.65 M(+19.2%) | $10.41 M(+1.7%) |
| Mar 2023 | - | $2.23 M(-9.6%) | $10.23 M(-5.8%) |
| Dec 2022 | $10.87 M(+16.8%) | $2.46 M(-19.6%) | $10.87 M(-0.6%) |
| Sep 2022 | - | $3.06 M(+23.7%) | $10.94 M(+14.8%) |
| Jun 2022 | - | $2.48 M(-13.3%) | $9.53 M(-0.5%) |
| Mar 2022 | - | $2.86 M(+12.8%) | $9.57 M(+2.9%) |
| Dec 2021 | $9.30 M(-0.5%) | $2.54 M(+52.8%) | $9.30 M(-1.4%) |
| Sep 2021 | - | $1.66 M(-34.2%) | $9.44 M(-9.2%) |
| Jun 2021 | - | $2.52 M(-2.6%) | $10.40 M(+8.5%) |
| Mar 2021 | - | $2.59 M(-3.1%) | $9.58 M(+2.4%) |
| Dec 2020 | $9.36 M(+61.4%) | $2.67 M(+2.0%) | $9.36 M(+14.6%) |
| Sep 2020 | - | $2.62 M(+53.5%) | $8.16 M(+15.2%) |
| Jun 2020 | - | $1.71 M(-27.7%) | $7.09 M(+6.0%) |
| Mar 2020 | - | $2.36 M(+59.6%) | $6.68 M(+15.3%) |
| Dec 2019 | $5.80 M(+0.5%) | $1.48 M(-4.1%) | $5.80 M(-1.7%) |
| Sep 2019 | - | $1.54 M(+18.4%) | $5.89 M(+5.1%) |
| Jun 2019 | - | $1.30 M(-11.5%) | $5.61 M(-5.1%) |
| Mar 2019 | - | $1.47 M(-6.7%) | $5.91 M(+2.5%) |
| Dec 2018 | $5.77 M(+43.5%) | $1.58 M(+25.5%) | $5.77 M(+4.5%) |
| Sep 2018 | - | $1.26 M(-21.7%) | $5.52 M(+0.6%) |
| Jun 2018 | - | $1.61 M(+20.8%) | $5.49 M(+21.4%) |
| Mar 2018 | - | $1.33 M(+0.1%) | $4.52 M(+12.5%) |
| Dec 2017 | $4.02 M(+42.0%) | $1.33 M(+8.6%) | $4.02 M(+33.2%) |
| Sep 2017 | - | $1.22 M(+91.3%) | $3.02 M(+14.2%) |
| Jun 2017 | - | $640.00 K(-22.8%) | $2.64 M(-6.8%) |
| Mar 2017 | - | $829.00 K(+153.5%) | $2.84 M(+0.1%) |
| Dec 2016 | $2.83 M(-21.0%) | $327.00 K(-61.4%) | $2.83 M(-7.9%) |
| Sep 2016 | - | $848.00 K(+1.9%) | $3.08 M(-6.7%) |
| Jun 2016 | - | $832.00 K(+0.7%) | $3.30 M(-4.5%) |
| Mar 2016 | - | $826.00 K(+44.7%) | $3.45 M(-3.7%) |
| Dec 2015 | $3.59 M(+35.4%) | $571.00 K(-46.5%) | $3.59 M(-11.2%) |
| Sep 2015 | - | $1.07 M(+8.1%) | $4.04 M(+5.5%) |
| Jun 2015 | - | $988.00 K(+2.9%) | $3.83 M(+17.5%) |
| Mar 2015 | - | $960.00 K(-6.2%) | $3.26 M(+23.0%) |
| Dec 2014 | $2.65 M(+24.6%) | $1.02 M(+19.2%) | $2.65 M(+21.6%) |
| Sep 2014 | - | $858.00 K(+105.8%) | $2.18 M(+36.8%) |
| Jun 2014 | - | $417.00 K(+18.8%) | $1.59 M(-17.0%) |
| Mar 2014 | - | $351.00 K(-36.4%) | $1.92 M(-9.8%) |
| Dec 2013 | $2.13 M | $552.00 K(+102.9%) | $2.13 M(+10.4%) |
| Sep 2013 | - | $272.00 K(-63.4%) | $1.93 M(-8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | $743.00 K(+32.9%) | $2.09 M(+16.4%) |
| Mar 2013 | - | $559.00 K(+59.3%) | $1.80 M(+2.8%) |
| Dec 2012 | $1.75 M(-20.7%) | $351.00 K(-20.2%) | $1.75 M(-18.4%) |
| Sep 2012 | - | $440.00 K(-1.8%) | $2.14 M(-5.5%) |
| Jun 2012 | - | $448.00 K(-12.2%) | $2.27 M(-14.4%) |
| Mar 2012 | - | $510.00 K(-31.6%) | $2.65 M(+10.5%) |
| Dec 2011 | $2.21 M(+42.8%) | $746.00 K(+32.3%) | $2.40 M(+4.5%) |
| Sep 2011 | - | $564.00 K(-32.0%) | $2.29 M(+15.1%) |
| Jun 2011 | - | $829.00 K(+221.3%) | $1.99 M(+39.2%) |
| Mar 2011 | - | $258.00 K(-59.8%) | $1.43 M(-7.3%) |
| Dec 2010 | $1.54 M(-1.6%) | $642.00 K(+143.2%) | $1.54 M(-2.8%) |
| Sep 2010 | - | $264.00 K(-1.5%) | $1.59 M(-3.3%) |
| Jun 2010 | - | $268.00 K(-27.6%) | $1.64 M(-2.7%) |
| Mar 2010 | - | $370.00 K(-46.1%) | $1.69 M(+7.6%) |
| Dec 2009 | $1.57 M(-3.7%) | $686.00 K(+115.7%) | $1.57 M(+44.7%) |
| Sep 2009 | - | $318.00 K(+1.3%) | $1.08 M(-7.4%) |
| Jun 2009 | - | $314.00 K(+25.1%) | $1.17 M(-12.4%) |
| Mar 2009 | - | $251.00 K(+24.9%) | $1.34 M(-18.0%) |
| Dec 2008 | $1.63 M(-45.5%) | $201.00 K(-50.4%) | $1.63 M(-30.6%) |
| Sep 2008 | - | $405.00 K(-15.4%) | $2.35 M(-16.4%) |
| Jun 2008 | - | $479.00 K(-11.9%) | $2.81 M(+0.8%) |
| Mar 2008 | - | $544.00 K(-40.9%) | $2.79 M(-6.8%) |
| Dec 2007 | $2.99 M(+39.7%) | $920.00 K(+6.4%) | $2.99 M(+44.4%) |
| Sep 2007 | - | $865.00 K(+89.3%) | $2.07 M(+13.4%) |
| Jun 2007 | - | $457.00 K(-38.9%) | $1.83 M(-8.8%) |
| Mar 2007 | - | $747.80 K(+20.4%) | $2.00 M(-18.7%) |
| Dec 2006 | $2.14 M(-12.8%) | - | - |
| Sep 2006 | - | $621.00 K(-1.8%) | $2.46 M(-3.3%) |
| Jun 2006 | - | $632.30 K(0.0%) | $2.54 M(+3.7%) |
| Mar 2006 | - | $632.30 K(+10.0%) | $2.45 M(+1.5%) |
| Mar 2006 | $2.45 M(-0.9%) | - | - |
| Dec 2005 | - | $574.80 K(-18.4%) | $2.42 M(+12.7%) |
| Sep 2005 | - | $704.60 K(+29.9%) | $2.15 M(-28.8%) |
| Jun 2005 | - | $542.30 K(-9.0%) | $3.02 M(+21.9%) |
| Mar 2005 | $2.48 M(+6703.8%) | $596.20 K(+97.0%) | $2.47 M(+31.8%) |
| Dec 2004 | - | $302.70 K(-80.8%) | $1.88 M(+18.6%) |
| Sep 2004 | - | $1.57 M(>+9900.0%) | $1.58 M(+4894.6%) |
| Dec 2003 | - | $8700.00(+70.6%) | $31.70 K(-8.9%) |
| Sep 2003 | - | $5100.00(-19.0%) | $34.80 K(-6.7%) |
| Jun 2003 | - | $6300.00(-45.7%) | $37.30 K(+2.5%) |
| Mar 2003 | $36.40 K(+52.9%) | $11.60 K(-1.7%) | $36.40 K(+46.8%) |
| Dec 2002 | - | $11.80 K(+55.3%) | $24.80 K(+90.8%) |
| Sep 2002 | - | $7600.00(+40.7%) | $13.00 K(+140.7%) |
| Jun 2002 | - | $5400.00 | $5400.00 |
| Mar 2002 | $23.80 K | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual SGA?
- What is the all time high annual SGA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual SGA year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly SGA year-on-year change?
- What is Brainstorm Cell Therapeutics TTM SGA?
- What is the all time high TTM SGA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM SGA year-on-year change?
What is Brainstorm Cell Therapeutics annual SGA?
The current annual SGA of BCLI is $10.69 M
What is the all time high annual SGA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual SGA is $10.87 M
What is Brainstorm Cell Therapeutics annual SGA year-on-year change?
Over the past year, BCLI annual SGA has changed by -$173.00 K (-1.59%)
What is Brainstorm Cell Therapeutics quarterly SGA?
The current quarterly SGA of BCLI is $2.00 M
What is the all time high quarterly SGA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly SGA is $3.11 M
What is Brainstorm Cell Therapeutics quarterly SGA year-on-year change?
Over the past year, BCLI quarterly SGA has changed by -$57.00 K (-2.77%)
What is Brainstorm Cell Therapeutics TTM SGA?
The current TTM SGA of BCLI is -$878.04 M
What is the all time high TTM SGA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM SGA is -$51.20 K
What is Brainstorm Cell Therapeutics TTM SGA year-on-year change?
Over the past year, BCLI TTM SGA has changed by -$887.43 M (-9456.83%)